The burden that Parkinson's disease (PD) exacts on the population continues to increase
year after year. Though refinement of symptomatic treatments continues at a reasonable …

Biomarkers that can guide cancer therapy based on patients' individual cancer molecular
signature can enable a more effective treatment with fewer adverse events. Data on …

Huntington's disease (HD) is a progressive and autosomal dominant neurodegeneration
caused by CAG expansion in the huntingtin gene (HTT), but the pathophysiological …

Exosomes represent a subtype of extracellular nanovesicles that are generated from the
luminal budding of limiting endosomal membranes and subsequent exocytosis. They …

3-3s are a family of adaptor proteins with a wide range of roles in cell signaling. Although
they are primarily localized within the cytosol, 14-3-3s are also known to be present in the …

Background Identifying PD‐specific biomarkers in biofluids will greatly aid in diagnosis,
monitoring progression, and therapeutic interventions. PD biomarkers have been limited by …

Binding of 14-3-3 proteins to leucine-rich repeat protein kinase 2 (LRRK2) is known to be
impaired by many Parkinson's disease (PD)-relevant mutations. Abrogation of this …

Mutations in the multidomain protein Leucine-rich-repeat kinase 2 (LRRK2) have been
identified as a genetic risk factor for both sporadic and familial Parkinson's disease (PD) …

Extracellular vesicles (EVs) are naturally occurring membranous structures secreted by
normal and diseased cells, and carrying a wide range of bioactive molecules. In the central …

Extracellular vesicles have been identified as pivotal mediators of intercellular
communication with critical roles in physiological and pathological conditions. Via this route …